TwentyFour Income Fund Limited (TFIF:LSE) delivered a strong investor update, showcasing consistent performance and disciplined portfolio management across the European asset-backed securities (ABS) and collateralised loan obligation (CLO) markets. With a market capitalisation of around £880 million and a 12.3% gross yield, the Fund continues to generate robust income from higher-yielding, floating-rate Western European assets. Since its 2013 launch, it has achieved an average annualised return of 8.1%, outperforming major benchmarks while maintaining low costs and active risk management. The Board reaffirmed the 8% annual dividend target—paid quarterly—and introduced a revised total return objective of UK base rate plus 6–8%, equivalent to 10–12% in the current rate environment. The portfolio remains diversified, with new opportunities in US CLOs (aligned with European regulations) and Australian mortgage-backed securities to enhance liquidity and returns. Management emphasised its focus on prime residential mortgages and senior secured loans while reducing exposure to unsecured consumer credit and commercial real estate. With a 2025 year-to-date performance above 8% and a 12.3% book yield, the Fund offers strong income coverage and low duration risk. The presentation also outlined details of the upcoming realization and open offer process, reinforcing the Fund’s robust discount control mechanism. Positioned to capitalise on growth in the European ABS market, TwentyFour Income Fund continues to deliver sustainable dividends, attractive total returns, and reliable income for investors seeking exposure to high-quality, floating-rate credit assets.

Xeros Technology Group PLC (AIM: XSG), a leader in sustainable washing and filtration technologies, delivered a strong investor presentation highlighting major commercial milestones, expanded global partnerships, and a pathway to scalable revenue growth. The company announced a landmark product launch agreement with one of the world’s largest domestic washing machine OEMs, marking its entry into the global consumer laundry market and setting the stage for commercial rollout in 2026. Three further agreements are in advanced negotiation, significantly reducing customer concentration risk and broadening future revenue visibility. Xeros’ care technology, centred on its patented XOrb polymer beads, enables major reductions in water, energy, and chemical use while extending garment life — addressing key sustainability challenges in the $100bn global laundry and apparel markets. The company’s XFilter technology, capable of capturing up to 99% of microplastics from washing machine wastewater, continues to gain traction through partnerships with Russell Hobbs, a leading European appliance retailer, and a major global washing machine manufacturer. Legislative momentum across the EU, UK, and U.S. to mandate microfibre filtration offers significant long-term market potential. In garment finishing, commercialisation is advancing through partnerships with Yilmak Makina and denim producer Ambition Apparel, delivering over 20% cost savings and 30% CO₂ reductions compared with traditional pumice-based processes. Financially, Xeros reported disciplined cost control, with administrative expenses and net cash outflow down over 30%, and a monthly burn rate of around £250k. With multiple blue-chip partners, proven IP protection across 38 patent families, and a scalable licensing model requiring limited capital investment, Xeros is now positioned for commercial acceleration. Management reaffirmed confidence in achieving sustainable revenue growth and profitability as adoption of its clean technology solutions expands globally across laundry, filtration, and apparel manufacturing.

Portmeirion Group PLC (PMP:AIM) delivered a resilient interim performance for 2025, with group sales up nearly 3% at constant currency and 11% excluding the US, reflecting solid progress in its transformation plan despite tariff-related disruption in its largest market. The company reported a £2.8m first-half loss, primarily driven by US tariffs, but achieved improved free cash flow and maintained tight overhead control amid inflationary pressures. Strong performances from its Wax Lyrical home fragrance division, which grew 15% and returned to profitability, and double-digit international growth, including a 31% rebound in South Korea, underpinned results. Management acted swiftly to mitigate tariff impacts through onshoring production to the UK, repricing products, and enhancing supply chain resilience, while continuing to invest in its premium brands Spode and Portmeirion through refreshed packaging, digital assets, and marketing initiatives. The group also secured a revised revolving credit facility with Barclays to support working capital and liquidity. CEO Mike Raybould highlighted continued progress on the five-point transformation strategy focused on restoring growth, strengthening the balance sheet, reducing net debt, expanding internationally, and driving operational excellence. Despite short-term margin pressure from reshoring and higher energy costs, Portmeirion expects modest second-half growth outside the US and remains confident in its long-term strategy, brand equity, and ability to deliver sustainable profitability. 

Pollen Street Group Limited (POLN:AIM) delivered a strong interim performance for 2025, reporting robust earnings growth, record fundraising and significant expansion across both private equity and private credit strategies. Total assets under management (AUM) rose 35% year-on-year to £6.1 billion, with fee-paying AUM up 37% to £4.7 billion, driven by strong investor demand and disciplined deployment. Private Equity Fund V closed at €1.5 billion, ahead of its €1 billion target, supported by high demand from North American investors, while Private Credit Fund IV raised £600 million by June and remains on track to exceed £1 billion in the second half. Management fee income increased 55% to £41.4 million, propelling a 112% rise in fund management EBITDA to £17.7 million and expanding margins to 43%. Recurring management fees now represent 76% of group revenues, strengthening earnings visibility and resilience, while total capital returned to shareholders since January 2024 reached £70 million through dividends and buybacks, including a 27 pence interim dividend. The business continues to benefit from strong fundraising momentum and a diversified investor base across North America, the Middle East and Asia, underpinned by sector specialism, disciplined pricing and focus on delivering alpha. Both private equity and credit strategies delivered healthy deployment, with 2 new platform investments, 7 bolt-on acquisitions and 14 credit transactions completed in the first half. Supported by a strong balance sheet, operational gearing and growing recurring income, Pollen Street is firmly on track to achieve its strategic objectives and medium-term target of £10 billion AUM. The group reaffirms its full-year guidance, highlighting continued growth in management fees, resilient margins and an attractive order book. Pollen Street’s scalable asset management platform, focus on sustainable profitability and disciplined capital allocation position it to deliver long-term value for investors and shareholders alike.

Aeorema Communications PLC (AEO:AIM), the global award-winning strategic communications group with offices in London, New York, and Cannes, delivered a confident investor update highlighting a resilient performance and strong growth momentum. For the twelve months to June 2025, revenue remained stable at just over £20 million, supported by a robust June trading period, while underlying profit before tax rose 41% to £615,000. The company reported a healthy cash position of £3.1 million and declared a 3% interim dividend payable in November, reflecting its continued commitment to shareholder returns.

Aeorema’s restructuring programme has streamlined operations, reduced costs, and positioned the business for enhanced efficiency and profitability into FY2026. The group’s growth strategy focuses on expanding its North American operations, where it has produced major live events for clients including the Wall Street Journal, Instacart, and Smartly, as well as high-profile global activations such as Climate Week NYC. Average project values have increased significantly, supported by deeper client relationships and a strong order pipeline.

Fully embracing AI-driven efficiencies across creative, production, and legal functions, Aeorema is also benefiting from the sector’s growth as both a user and supplier to leading technology and AI companies. With sustained demand for high-impact, in-person brand experiences and an expanding international footprint, the company remains confident in its outlook and plans to release full-year forecasts by year-end. Aeorema continues to demonstrate robust cash generation, disciplined management, and strategic agility, underpinning its position as a market leader in live communications and experiential marketing.

Inspiration Healthcare Group PLC delivered record first-half FY26 financial results, achieving revenue of £24 million, up 41% year-on-year, driven by major contracts in the Middle East and UNICEF. The company returned to profitability, reporting EBITDA of £1.3 million versus a prior-year loss, with gross margins improving to 46.2% and operating cash flow rising to £3.6 million. Net debt reduced by £1.6 million to £6.7 million, supported by strong working capital improvements and inventory reduction. Underlying business growth remained solid, particularly across international markets in Asia-Pacific and Europe, while UK revenues are expected to strengthen in H2 following the resolution of short-term supply constraints. The Group’s “Back to Basics” strategy continues to enhance operational efficiency, profitability, and customer focus through ERP system upgrades and tighter supply chain management. Looking ahead, Inspiration Healthcare is targeting sustained growth across three focused divisions: SLE, as a global leader in neonatal ventilation; Inspiration Healthcare, as a key UK MedTech distributor and infusion therapy provider; and Aeron, as a specialist in pneumatic ventilators. The company aims to double revenues by 2030 through organic growth, expanding recurring revenues from consumables and services, and entering the high-margin US market with its flagship SLE6000 ventilator. With a clear growth strategy, strong order pipeline, and improved margins, Inspiration Healthcare expects to meet full-year market expectations and deliver long-term shareholder value through disciplined execution, enhanced operational efficiency, and innovation in neonatal care technologies.

CG Asset Management’s Q3 2025 investor update highlighted a disciplined, defensive investment strategy amid elevated equity valuations, AI-driven capital expenditure, and growing fiscal risks in major economies. The firm reported positive overall performance across most asset classes, supported by selective exposure to UK, Japanese, and emerging market investment trusts, while maintaining historically low risk-asset allocations. Liquidity reserves remain strong, with yields above 5.8% on short-dated corporate credit, creating a high hurdle for new investments. Portfolio Manager Hassan Raza detailed an increased 6% allocation to UK index-linked bonds, funded by the reallocation of hedged US TIPS, and emphasized a shorter duration strategy—6.5 years versus 14 years for the index—to mitigate long-end yield risks as the UK’s fiscal outlook deteriorates. Proceeds from the sale of renewable infrastructure holdings were reinvested into core infrastructure assets such as INPP, HICL, and 3i Infrastructure, while successful engagement with investment trusts like Fidelity Japan Value narrowed discounts and supported NAV growth. Co-Chief Investment Officer Chris Clothier cautioned that US equity markets appear historically expensive, with the cyclically adjusted price-to-earnings ratio at 38x, suggesting weak long-term real returns. He expressed concern that the scale of AI-related capital expenditure, estimated at $500 billion annually, may represent a significant misallocation of capital, potentially leading to disappointing returns and heightened volatility. Fiscal deficits and debt-to-GDP ratios in the UK, US, and France were also flagged as major vulnerabilities that could trigger bond market or fiscal crises, reinforcing CGAM’s preference for shorter-duration inflation-linked bonds and high-quality credit positions. During Q&A, management reaffirmed a low weighting to gold, ongoing caution toward renewable energy trusts, and a focus on inflation-linked securities over nominal bonds. Overall, CG Asset Management underscored its disciplined, risk-aware approach to capital preservation, yield optimization, and identifying selective long-term value opportunities across global markets.

Verici Dx Plc (AIM: VRCI), a leader in kidney transplant diagnostics, reported strong momentum in its Interim Results for the first half of 2025, marking a pivotal transition from milestone-driven development to commercial growth. The company’s lead RNA-based diagnostic test, Tutivia, achieved a major milestone with Medicare coverage approval at a reimbursement rate of $2,650, enabling full commercial revenue recognition and accelerating cash collection. This breakthrough provides access to approximately 68% of the US transplant market and validates Tutivia’s clinical value as an earlier, more precise biomarker for transplant rejection compared to incumbent DNA-based tests. During the period, Verici Dx generated £1.1 million in Tutivia revenues and received a £750,000 milestone payment from its Thermo Fisher partnership, while a £6.3 million fundraise in July extended the company’s cash runway through the second half of 2026. Gross margins remain strong at 70%, supported by efficient operations and growing test adoption. The commercial rollout gained momentum with a 19% increase in clinician users and expansion to 30 active transplant centers, with testing volumes expected to accelerate into Q4 2025. Verici’s differentiated RNA technology positions it to serve a $900 million addressable US market, targeting unmet clinical needs among high-risk and complex transplant patients. The company continues to advance its broader product portfolio, including Protega, a long-term graft monitoring test in development, and Petr, a pre-transplant test licensed to Thermo Fisher. The company highlighted the company’s strengthened salesforce, accelerating hospital onboarding, and growing credibility among clinicians as key drivers of near-term growth. With robust reimbursement in place, expanding market access, and increasing demand for precision diagnostics, Verici Dx is well-positioned for sustained revenue growth, margin improvement, and long-term leadership in the global kidney transplant diagnostics market as it continues to build commercial scale through 2026.

Animalcare Group plc (ANCR:AIM) reported strong interim results for FY2025, with revenue up 18.3% and continued progress across its diversified veterinary pharmaceuticals portfolio. Growth was driven by the successful integration of Randlab, which delivered 14% revenue growth, a 73% gross margin, and a 47% EBITDA margin, significantly enhancing Group profitability. Organic performance remained solid despite FX headwinds and a temporary regulatory issue in Spain.

CEO Jenny Winter and CFO Chris Brewster highlighted the Group’s three-pillar growth strategy: driving organic growth through key brands such as Daxocox and Plaqtiv+ (up 39% in H1), pursuing strategic M&A with £20–25m of available capital, and advancing a strong R&D pipeline targeting novel, high-margin products from 2030 onwards. The Randlab acquisition expanded Animalcare’s equine and production animal portfolio across Australia, New Zealand, the UAE, and Asia-Pacific, strengthening its global presence.

The Group maintained 70% cash conversion, 0.7x leverage, and strong EPS growth, supported by disciplined cost control and tax efficiencies. Investment in R&D is set to rise to around 5% of revenue, while the company maintains a sustainable dividend policy.

With a resilient balance sheet, expanding order book, and a focus on innovation, Animalcare is positioned for continued double-digit profit growth, improved EBITDA margins, and long-term shareholder value creation.

Tortilla Mexican Grill PLC (MEX:AIM) delivered its Interim 2025 results with a strong update on trading performance, growth strategy, and European expansion. Despite a challenging UK market, the group reported revenue of £36m for H1, up 14% year-on-year, with system sales reaching £50m. Like-for-like sales grew 5%, outperforming the industry by over 8 percentage points, while UK adjusted EBITDA rose more than 30% to £2.4m, driving record profitability and margins. Strategic initiatives under the “Vital Five” pillars—improving UK profitability, enhancing brand and product, investing in people and technology, expanding franchising, and developing internationally—continue to deliver results. Over half of UK stores now feature self-ordering kiosks, driving a 10% sales uplift, while the Burrito Society loyalty app has grown to nearly 250,000 members. Franchising momentum remains strong, with SSP, Compass, and Ethos partnerships delivering double-digit growth, and new pilot sites with Growth Kitchen underway. International expansion advanced with six French store conversions, supported by a new central kitchen in Lille capable of supplying several hundred locations, positioning Tortilla as Europe’s largest burrito brand. Management highlighted improved staff retention, innovative menu launches, and strategic marketing as key drivers of customer engagement. While the French investment phase weighed on group EBITDA, the UK remains a robust cash-generating engine to fund growth. Looking ahead, the company expects continued momentum in UK like-for-like sales (up 7% in Q3), further franchise openings in Glasgow and Dubai, and expanded European opportunities across France, Germany, Belgium, Netherlands, Spain, and Portugal. With record UK profitability, strong order book growth, and scalable infrastructure in place, Tortilla is well-positioned to deliver long-term shareholder value.